TOKYO–(BUSINESS WIRE)–Mitsubishi UFJ Financial Group, Inc. (NYSE:MUFG)(TOKYO:8306)(ISIN:JP3902900004)(MUFG) hereby announces that it has filed its Annual Report on Form 20-F for the fiscal year ended March 31, 2022 (the �Annual Report) with the U.S. Securities and Exchange Commission on July 8, 2022. The Annual Report includes MUFGs audited consolidated financial statements prepared under U.S. GAAP as of and for the fiscal year ended March 31, 2022.
The Annual Report is available on our website at the following website address:
https://www.mufg.jp/english/ir/report/form20-f/
In addition, all shareholders may receive a hard copy of the Annual Report free of charge upon request at our website. Such request should be made to below:
https://form.mufg.jp/regist/is?SMPFORM=nbp-mjsim-0e521dfd17a26a22a6e6d64d664bdb65
Contacts
Mitsubishi UFJ Financial Group, Inc.
Masahisa Takahashi,
Managing Director, Head of Financial Accounting and Reporting, Financial Accounting Office, Financial Planning Division
Tel: +81-3-3240-8111
Exceeds Guidance Ranges with Record Revenue and Net Income Per Share BANGKOK--(BUSINESS WIRE)--Fabrinet (NYSE: FN),…
DUBLIN--(BUSINESS WIRE)--The "South Korea Data Center Market - Investment Analysis & Growth Opportunities 2024-2029" report…
GUANGZHOU, China--(BUSINESS WIRE)--On May 3rd and 4th, the Guangzhou Opera House welcomed nearly 200 international…
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--BrainChip Holdings Ltd (ASX: BRN, OTCQX: BRCHF, ADR: BCHPY), the world’s first…
SAN JOSE, Calif.--(BUSINESS WIRE)--NetApp (NASDAQ: NTAP), the intelligent data infrastructure company, today announced Dallas Olson…
BEIJING--(BUSINESS WIRE)--#Antibody--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315), a global biotechnology company focused on…